Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $99.80 USD
Change Today +1.28 / 1.30%
Volume 3.8M
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for novartis ag-sponsored adr (NVS)

Year over year, Novartis AG has seen revenues remain relatively flat ($52.1B USD to $52.4B USD), though the company was able to grow net income from $9.2B USD to $10.2B USD. A reduction in the percentage of sales devoted to selling, general and administrative costs from 29.16% to 28.44% was a key component in the bottom line growth in the face of flat revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Dec 31
2012
Restated
Dec 31
2013
Restated
Dec 31
2014
4 Year
Trend
Revenues58,566.051,330.052,090.052,419.0
Other Revenues809.0641.0626.01,215.0
TOTAL REVENUES59,375.051,971.052,716.053,634.0
Cost of Goods Sold18,571.015,586.016,539.017,203.0
GROSS PROFIT40,804.036,385.036,177.036,431.0
Selling General & Admin Expenses, Total18,047.015,102.015,189.014,907.0
R&D Expenses9,332.08,465.08,946.08,771.0
Other Operating Expenses661.0433.0571.0833.0
OTHER OPERATING EXPENSES, TOTAL28,040.024,000.024,706.024,511.0
OPERATING INCOME12,764.012,385.011,471.011,920.0
Interest Expense-751.0-724.0-683.0-704.0
Interest and Investment Income63.051.035.034.0
NET INTEREST EXPENSE-688.0-673.0-648.0-670.0
Income (Loss) on Equity Investments528.0549.0599.01,918.0
Currency Exchange Gains (Loss)98.0-149.0-88.023.0
Other Non-Operating Income (Expenses)-38.0-20.0-22.0-25.0
EBT, EXCLUDING UNUSUAL ITEMS12,664.012,092.011,312.013,166.0
Merger & Restructuring Charges-326.0-464.0-352.0-196.0
Gain (Loss) on Sale of Investments-317.041.027.0246.0
Gain (Loss) on Sale of Assets----313.0283.0
Other Unusual Items, Total-1,248.0-433.0-493.0-1,227.0
Insurance Settlements85.0------
Legal Settlements-101.0-19.0-118.0-155.0
Other Unusual Items-217.0-250.0-222.0-751.0
EBT, INCLUDING UNUSUAL ITEMS10,773.011,236.010,807.012,272.0
Income Tax Expense1,528.01,706.01,498.01,545.0
Minority Interest in Earnings-132.0-113.0-117.0-70.0
Earnings from Continuing Operations9,245.09,530.09,309.010,727.0
EARNINGS FROM DISCOUNTINUED OPERATIONS---147.0-17.0-447.0
NET INCOME9,113.09,270.09,175.010,210.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS9,113.09,270.09,175.010,210.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS9,113.09,417.09,192.010,657.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $99.80 USD +1.28

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $115.04 USD -0.97
Johnson & Johnson $98.44 USD -0.03
Nestle SA SFr.68.60 CHF -0.40
Pfizer Inc $33.37 USD -0.32
Roche Holding AG SFr.265.10 CHF -1.30
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.0x
Price/Sales 4.5x
Price/Book 3.1x
Price/Cash Flow 13.0x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.